Labcorp completes acquisition of personal genome diagnostics

Burlington, n.c.--(business wire)--labcorp (nyse: lh), a leading global life sciences company, today announced that it has closed its acquisition of personal genome diagnostics inc. (pgdx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products. the addition of pgdx and its technology complements and accelerates labcorp's existing liquid biopsy capabilities and expands labcorp's leading oncology portfolio of next-generation sequencing (ngs)-based g
LH Ratings Summary
LH Quant Ranking